Can third party CMV-specific T-cells replace drug therapy? No

During the last years major advances have been achieved in using antiviral drugs for prevention and therapy of CMV infection and disease in allogeneic stem cell transplant recipients. Letermovir was shown in a randomized, controlled study to be highly efficacious for prevention of CMV reactivation and also decreased all cause mortality with a very good safety profile. Maribavir was shown to be effective for treating resistant CMV infection and disease also with an excellent safety profile. These two advances will make the need for third party T-cells limited.